Publications by authors named "Bjarke R Medici"
Article Synopsis
- The study investigates the link between hypothyroidism and oxidative stress, focusing on biomarkers 8-oxoGuo and 8-oxodG, which indicate RNA and DNA oxidation, respectively.
- 45 Danish women with newly diagnosed hypothyroidism were compared before and after treatment with levothyroxine, along with healthy control subjects to assess changes in these biomarkers.
- Results showed no significant changes in oxidative stress markers after initiating treatment in patients, although hypothyroid women had higher levels of 8-oxoGuo and 8-oxodG compared to the control group.
Context: In individuals with hypothyroidism and overweight, levothyroxine substitution therapy is often expected to cause weight loss due to its effect on resting energy expenditure. However, despite levothyroxine-induced enhancement of resting energy expenditure, fat mass loss is rarely seen after levothyroxine substitution therapy. The mechanism behind this conundrum is unknown.
View Article and Find Full Text PDFIntroduction: High compared with low educational level increases the odds of starting levothyroxine (L-T4) with a normal thyroid-stimulating hormone - the mechanism is most likely patient request. The use of liothyronine (L-T3) and desiccated thyroid extract (DTE) is also speculated to be initiated at patients' request. Therefore, the primary aim of this study was to evaluate if educational level influences treatment with L-T3 and DTE.
View Article and Find Full Text PDFObjective: A decrease over time in thyroid stimulating hormone (TSH) levels when initiating levothyroxine (L-T4) therapy for hypothyroidism has been reported, where treatment most often is initiated with TSH levels below 10 mIU/L. The primary objective of this study was to investigate whether this lower TSH threshold resulted in an increased number of overtreated patients.
Design And Method: Retrospective cohort study comprising inhabitants in Copenhagen had TSH measurements requested by general practitioners which led to a new prescription of L-T4 between 2001 and 2012.